5 research outputs found
Clathrate-Based CO<sub>2</sub> Capture from Co<sub>2</sub>‑Rich Natural Gas and Biogas
In this study, clathrate-based CO<sub>2</sub> capture was investigated
in the presence of thermodynamic promoters such as tetrahydrofuran
(THF) and tetra-<i>n</i>-butyl ammonium chloride (TBAC)
for upgrading CO<sub>2</sub>-rich natural gas and biogas. The phase
equilibria, gas uptakes, gas composition measurements, and spectroscopic
analyses of CH<sub>4</sub> (50%), CO<sub>2</sub> (50%), and promoter
clathrates were examined with a primary focus on the effects of thermodynamic
promoters on clathrate stability and cage filling behavior. The addition
of THF and TBAC significantly enhanced the thermodynamic stability
of CH<sub>4</sub> (50%) and CO<sub>2</sub> (50%) clathrates. <sup>13</sup>C NMR and Raman spectroscopy clearly revealed that CO<sub>2</sub> and CH<sub>4</sub> are enclathrated in the clathrate cages.
THF solutions demonstrated a faster growth rate of clathrates, but
CO<sub>2</sub> was less selective than CH<sub>4</sub> in the THF clathrate
phase due to the lower thermodynamic stability of the CO<sub>2</sub> and THF clathrate compared to the CH<sub>4</sub> and THF clathrate.
TBAC solutions produced higher CO<sub>2</sub> selectivity in the semiclathrate
phase due to the presence of distorted small cages, which have a strong
preference for CO<sub>2</sub> molecules. The experimental results
demonstrated that CO<sub>2</sub> selectivity in the clathrate phase
can be influenced by the thermodynamic stability, cage shape and dimension,
and cage filling behavior in the presence of thermodynamic promoters,
and thus, a suitable promoter and their optimum concentration should
be carefully determined in designing and operating clathrate-based
CO<sub>2</sub> capture from natural gas or biogas
Experimental schedule and disease phenotypes of R6/2 mice.
<p>(A) Schedule for ASCs-E injection, behavior test, weight measure and brain sampling. (B) ASCs-E injection mitigated weight loss in R6/2 mouse at 12 weeks age. (C) Rotarod test showed better motor performance at 10, 11 and 12 weeks of age in ASCs-E treated R6/2 compared with control. * <i>p</i><0.05, ** <i>p</i><0.01.</p
Additional file 1: of Association between sleep duration and metabolic syndrome: a cross-sectional study
Table S1. Odds ratios (ORs)a of metabolic syndrome by sleep duration, the Health Examinees-Gem (HEXA-G) study 2009-2013b. (DOCX 32 kb
Restoration of p-Akt, CREB and PGC-1α by ASCs-E.
<p>(A) Western blot analysis confirmed that upregulation of PGC-1α, p-CREB and p-Akt in ASCs-E treated R6/2 mice brain and (B) PGC-1α and p-CREB in ASCs-E treated neuro2A cells. Bar graphs show the relative levels of protein expressions normalized to β-actin. * <i>p</i><0.05.</p
Striatal atrophy and mHtt aggregation.
<p>(A) Striatal mHtt aggregation was mitigated in ASCs-E treated group. (B) mHtt aggregation was visualized by western blot. (C) mHtt aggregation level was higher in ASCs-E treated R6/2 mouse brain compared with R6/2 control. (D) Striatum was sectioned and stained with Nissl in R6/2 mouse treated with ASCs-E or vehicle. (E) Striatum/peristriatum ratio is higher in ASCs-E injected group compared with vehicle treated group. Bar = 100 μm, * <i>p</i><0.01.</p